News Releases

Date	Title and Summary	View
Dec 17, 2018	Johnson & Johnson Announces $5 Billion Share Repurchase Program NEW BRUNSWICK, N.J. , Dec. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. "Based on our continued strong performance and, more importantly, the confidence we have in
Dec 14, 2018	Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients If approved, this will add to the five existing VTE indications for XARELTO® – the most studied anticoagulant available to the most groups of patients Despite being largely preventable, VTE remains a significant risk for the eight million Americans with acute medical illnesses TITUSVILLE,
Dec 14, 2018	Statement on Reuters Talc Article NEW BRUNSWICK, N.J. , Dec. 14, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today issued the following statement regarding speculation about the safety of our products. The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and asbestos-free.
Dec 12, 2018	New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48 84.5 percent of patients receiving TREMFYA achieved the primary endpoint of a PASI 90 response at week 48 compared with 70.0 percent of patients receiving Cosentyx ECLIPSE is the first Phase 3 head-to-head study to compare efficacy between the first-in-class IL-23 inhibitor, TREMFYA, and the IL-17
Dec 04, 2018	New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of AntiCD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Dec 03, 2018	IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dec 03, 2018	Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
Dec 03, 2018	Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Nov 26, 2018	Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference NEW BRUNSWICK, N.J. , Nov. 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12 th , at The Mandarin Oriental, New York. Ciro Römer, Company Group Chairman for the Johnson & Johnson Medical
Nov 16, 2018	Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease